Although prostate cancer initially responds and regresses in response to androgen-depletion therapy, most human prostate cancers will re-grow as an androgen-independent tumour. The goal of our study ...

Gene therapy has often been described as a “black box” technique; that is, it is not known what happens to the cell after vector-mediated gene transfer. Although expression levels of the transgene are ...

In each type of cell, like a muscle cell or a skin cell, different genes are expressed (turned on) or silenced (turned off). If the cells that are turned on mutate, they could—depending on what role ...

Current microarray analysis uses 'chips' containing either 25-residue oligonucleotides synthesized by photolithography or cDNAs placed by robotic spotting. In the April Nature Biotechnology, Hughes et ...

The main steps involved and limitations of microarray analysis will be encountered. Two stages can be distinguished in microarray experiments: a pre-microarray experiment phase (tissue handling) and ...

In those days, there were a limited number of known genes to select from. "The first thing you want is genes that have a name and activity associated with them, because if one of those is indicated as ...

Yes, many are attracted to next-generation sequencing, but loyalty to chip-based phenotyping has its rewards, particularly in screens of large sample sets. The microarray, the legacy technology for ...

Background: This study evaluated effects of zinc on the hepatic lipid peroxidation, antioxidant components and mRNA expression levels in rats. Methods: Three diets with different Zn levels including ...

You are oncologists specializing in breast cancer and will be conducting a microarray analysis on one of two newly diagnosed breast cancer patients, Mrs. Jones and Mrs. Brown. You will be adding a ...

Technology Set to Compete with Microarrays in This Application Arena Microarray-based gene-expression profiling technology hardly seems like it has been around long enough for a new approach to come ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.